CASI Pharmaceuticals, Inc., a pharmaceutical company, develops pharmaceutical products and various therapeutics in China, the United States, and internationally.
The last earnings update was 20 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
CASI Pharmaceuticals. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
CASI Pharmaceuticals's earnings available for a low price, and how does
this compare to other companies in the same industry?
CASI Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
Unable to determine if CASI Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
CASI Pharmaceuticals's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
CASI Pharmaceuticals's finances.
The net worth of a company is the difference between its assets and liabilities.
CASI Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
CASI Pharmaceuticals's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
CASI Pharmaceuticals's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Debt is covered by short term assets, assets are 61.7x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Wei-Wu He, Ph.D. serves as Executive Chairman of CASI Pharmaceuticals, Inc. since February 23, 2018 and serves as its Chief Executive Officer since April 2019. Dr. He previously served as Chairman of CASI Pharmaceuticals, Inc. from May 2013 to February 23, 2018. Dr. He founded OriGene Technologies, Inc., in 1995 and serves as its Chairman & Chief Executive Officer. Dr. He is a Co-founder and General Partner of Emerging Technology Partners, LLC. He serves as Investment Partner of IDG Investment Company. Dr. He is one of the founding investors in Intradigm. He served as Chairman and Chief Executive Officer of Cytomyx Holdings plc since November 28, 2006. He worked at Human Genome Sciences, Inc. He served as President of OriGene Technologies, Inc. He serves as the Chairman of Genetron Health (Beijing) Co., Ltd. He served as the Chairman of Aptus Pharmaceuticals, Inc. He served as an Executive Chairman of CASI Pharmaceuticals, Inc. from February 2012 to May 2013. He has been Director of CASI Pharmaceuticals, Inc. since February 2012 and Human Longevity, Inc. since July 25, 2016. He serves as Director at MithraGen, Inc., Emerging Technology Partners, Origene Technologies, Inc., Intradigm, Inc., and Amnis, Inc. He served as Director at Adenosine Therapeutics, LLC, Clairus Technologies, Inc., Intradigm Corporation, Amnis Corporation, Aptus Pharmaceutical, Inc., and FasGen, Inc. He served as Director at InforMax, Inc., since August 2000. He has been awarded over 20 U.S. patents and has more than twenty original research publications. Dr. He received his Ph.D. in Molecular Biology from Baylor College of Medicine and conducted cancer research at Mayo Clinic and at Massachusetts General Hospital. Dr. He received an M.B.A. degree from the Wharton School.
Wei-Wu's compensation has been consistent with company performance over the past year.
Wei-Wu's remuneration is about average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the CASI Pharmaceuticals management team is about average.
Executive Chairman & CEO
COO, General Counsel & Secretary
Chief Medical Officer
Chief Financial Officer
VP of Finance & Principal Accounting Officer
Senior Vice President
President of CASI (Beijing) Pharmaceuticals Co.
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the CASI Pharmaceuticals board of directors is about average.
CASI Pharmaceuticals, Inc., a pharmaceutical company, develops pharmaceutical products and various therapeutics in China, the United States, and internationally. The company’s product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. Its product pipeline also comprises ZEVALIN, an ibritumomab tiuxetan injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-Hodgkin’s lymphoma, as well as for the treatment of patients with previously untreated follicular non-Hodgkin’s lymphoma; and MARQIBO, a microtubule inhibitor to treat adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. In addition, the company engages in the development of a portfolio of 26 FDA-approved abbreviated new drug applications (ANDAs), including entecavir and tenofovir disoproxil fumarate indicated for hepatitis B virus; and 4 pipeline ANDAs that are pending FDA approval. Further, it is involved in developing ENMD-2076, an Aurora A/angiogenic kinase inhibitor that has completed Phase II studies for solid tumors, as well as various proprietary early-stage immune-oncological potential candidates in preclinical development. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.